Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Safety Information For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… Lovenox (enoxaparin sodium) Injection, Aventis NDA 20-164/S51 6/20/03 7/6/03 | Lovenox (enoxaparin sodium) Injection, Aventis NDA 20-164/S50 7/1/03 7/8/03 | Lovenox (enoxaparin sodium) Injection, 300 mg/3.0, Aventis Products NDA 20-164/S43 1/23/03 1/27/03 | Lovenox (enoxaparin sodium) Injection, Aventis Products NDA 20-164/S40, S45 & S6 1/9/02 2/8/02 | Lovenox (enoxaparin sodium) Injection Aventis Products NDA 20-164/S036 11/17/00 11/27/00 11/27/00 | Lovenox (enoxaparin sodium) Injection Aventis Products NDA 20-164/S034 9/27/00 9/29/00 | Lovenox (enoxaparin sodium) Injection Aventis Products NDA 20-164/S020 8/4/00 8/4/00 | Lovenox (enoxaparin sodium) Injection Rhone-Poulenc Rorer NDA 20-164/S010 1/30/98 4/24/03 | Lovenox (enoxaparin sodium) Injection Rhone-Poulenc Rorer NDA 20-164/S015 12/31/98 7/3/00 | Lovenox (enoxaparin sodium) Injection, Subcutaneous (SC), or OTC: Rhone-Poulenc Rorer NDA 20-164 12/31/98 1/5/99 1/5/99 | Lovenox Indications:(1) the inpatient treatment of acute deep vein thrombosis with and without pulmonary embolism, when administered in conjunction with warfarin sodium, and (2) the outpatients treatment of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium. Lovenox (enoxaparin sodium) Injection, Aventis Pharmaceuticals | Lovenox (enoxaparin sodium) Injection, Aventis Pharmaceuticals Lovenox (enoxaparin sodium) Injection, Aventis Pharmaceuticals | Lovenox (enoxaparin sodium, injection), Aventis Pharmaceuticals, Control Supplement | Lovenox (enoxaparin sodium) injection, Aventis Pharma, Labeling Revision | Lovenox (enoxaparin sodium) Subcutaneous Injection, Sanofi-Aventis, Labeling Revision | Enoxaparin Sodium Subcutaneous Injection, Sandoz Inc., Approval | Lovenox (enoxaparin sodium) Subcutaneous I.V. Injection, Sanofi-Aventis U.S., LLC, Labeling Revision | Lovenox (enoxaparin sodium) Injection, Sanofi-Aventis U.S., LLC, Labeling Revision | Enoxaparin Sodium Injection, Amphastar Pharmaceuticals, Inc., Approval | Enoxaparin Sodium Subcutaneous Injection, Amphastar Pharmaceuticals, Inc., Approval | Enoxaparin Sodium Injection, Sandoz Inc., Approval | Lovenox, enoxaparin sodium, Injectable; Intravenous, Subcutaneous, Sanofi Aventis Us, Manufacturing Change or Addition | Lovenox (Preservative Free), enoxaparin sodium, Injectable; Subcutaneous, Sanofi Aventis Us, Manufacturing Change or Addition | Lovenox, enoxaparin sodium, Injectable; Intravenous, Subcutaneous, Sanofi Aventis Us, Manufacturing Change or Addition | Lovenox (Preservative Free), enoxaparin sodium, Injectable; Subcutaneous, Sanofi Aventis Us, Manufacturing Change or Addition | Lovenox, enoxaparin sodium, Injectable; Intravenous, Subcutaneous, Sanofi Aventis Us, Manufacturing Change or Addition | Lovenox (Preservative Free), enoxaparin sodium, Injectable; Subcutaneous, Sanofi Aventis Us, Manufacturing Change or Addition | Lovenox, enoxaparin sodium, Injectable; Intravenous, Subcutaneous, Sanofi Aventis Us, Labeling Revision | Lovenox (Preservative Free), enoxaparin sodium, Injectable; Subcutaneous, Sanofi Aventis Us, Labeling Revision ^ FDA's latest approval appears at the bottom of this list. ^                                                                       A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | For Industry | DMF Index | Pharma Job Search | Pharma Company News | Best Phone © 2013 Betterchem.com